Conv. Plasma
Nigella Sativa
Peg.. Lambda

All bromhexine studies
Meta analysis
Home COVID-19 treatment researchBromhexineBromhexine (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 93% Improvement Relative Risk Hospitalization 88% Recovery time 28% Bromhexine  Ghayour et al.  EARLY TREATMENT  RCT Is early treatment with bromhexine beneficial for COVID-19? RCT 150 patients in Iran (April - September 2022) Lower mortality (p=0.013) and hospitalization (p<0.0001) Ghayour et al., Research Square, January 2023 Favors bromhexine Favors control

Evaluation of the recovery rate and prevention of hospitalization among covid-19 outpatients: a randomized clinical trial comparing N-acetylcysteine with Bromhexine

Ghayour et al., Research Square, doi:10.21203/, IRCT20220302054167N1
Jan 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 225 outpatients in Iran showing lower mortality and hospitalization, and faster recovery with N-acetylcysteine and bromhexine. Baseline information per group is not provided, Figure 1 has the control group hospitalization status switched and the totals do not match, and the registration and previous version of this paper do not include the control group. N-acetylcysteine 600mg daily for 5 days, bromhexine 8mg tid for 5 days.
Bromhexine efficacy may vary depending on the degree of TMPRSS-dependent fusion for different variants Peacock, Willett. This study is excluded in meta analysis: inconsistent data, no baseline group details, control group not in previous version.
This study includes N-acetylcysteine and bromhexine.
risk of death, 93.3% lower, RR 0.07, p = 0.01, treatment 0 of 75 (0.0%), control 7 of 75 (9.3%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 88.0% lower, RR 0.12, p < 0.001, treatment 6 of 75 (8.0%), control 50 of 75 (66.7%), NNT 1.7.
recovery time, 28.5% lower, relative time 0.72, p < 0.001, treatment mean 10.76 (±0.64) n=75, control mean 15.04 (±8.557) n=75.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ghayour et al., 3 Jan 2023, Randomized Controlled Trial, Iran, preprint, mean age 58.6, 4 authors, study period April 2022 - September 2022, trial IRCT20220302054167N1.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBromhexineAll
Evaluation of the recovery rate and prevention of hospitalization among covid-19 outpatients: a randomized clinical trial comparing N-acetylcysteine with Bromhexine
Anahita Eslami Ghayour, Sasan Nazari, Fariba Keramat, Fatemeh Shahbazi
Objectives: Due to the referral of COVID-19 patients to outpatient centers in the early stages, the aim of the present study is to compare the effect of N-acetylcysteine and Bromhexine on the recovery rate and prevention of hospitalization in outpatients with Methodology: This study was conducted from April 2022 to September 2022. First, PCR-con rmed COVID-19 patients were divided into tree groups, one of these groups received N-acetylcysteine while the other received bromhexine and One of these groups did not receive any medication. The patients were followed up on the seventh and fourteenth days of the disease in terms of the duration of changes in oxygen saturation and recovery. The hospitalization and death of the patients were also evaluated after one month. Results: Out of 225 studied patients, oxygen saturation was increased by 1.33% in the third visit of the patients who received N-acetylcysteine compared to their rst visit. This percentage was 1.19% in the patients who received bromhexine.29.77% of the patients were admitted to the hospital and 70.23% of them had no history of hospitalization within 14 day and their mortality rate was 9.33% in control group and it was zero in both groups of patients who received drug. Conclusions: The results of this study showed that early initiation of Bromhexine and N-acetylcysteine can effectively reduce the hospitalization rate and mortality and shorten the duration of hospitalization.
However, more studies are still needed to prove their bene ts Declarations 6.1. Ethics approval and consent to participate: This study was approved by the Research Ethics Committees of Hamadan University of Medical Scienece with the ethics code: IR.UMSHA.REC.1400.957 and this study was approved by the judges of the International Center for Registration of Clinical Trials of Iran, a member of the international centers approved by the World Health Organization and with the code: IRCT20220302054167N1 Con rmed. Informed consent was obtained from all participating patients/their legal guardians in this study after fully explaining the study method, side effects of drugs and other necessary matters. All patients were rst examined in terms of drug allergy history, and then the study was fully explained to the patients, and the questions and doubts of the patients were fully answered, and it was also explained to the patients that for any reason, they wanted to continue participating in the study. do not have, they can withdraw, and this study will not interfere with their treatment. Also, all patients are assured that all their information is con dential and only collective information of the entire study is available. All methods were carried out in accordance with relevant guidelines and regulations. Consent for publication Not applicable. Availability data and materials All data generated or analyzed during this study are included in this published article. Competing..
Ansarin, Tolouian, Ardalan, Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial, Bioimpacts, doi:10.34172/bi.2020.27
Hesni, Sayad, Khosravi Shadmani, Demographics, clinical characteristics, and outcomes of 27,256 hospitalized COVID-19 patients in Kermanshah Province, Iran: a retrospective one-year cohort study, BMC Infect Dis, doi:10.1186/s12879-022-07312-7
Huang, Su, Theron, An interferon-gamma-related cytokine storm in SARS patients, J Med Virol, doi:10.1002/jmv.20255
Izquierdo, Soriano, González, Use of N-Acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19, Sci Prog, doi:10.1177/00368504221074574
Lee, Hong, Jang, N-acetylcysteine decreases airway in ammation and responsiveness in asthma by modulating claudin 18 expression, Korean J Intern Med, doi:10.3904/kjim.2019.105
Marchetti, Lodola, Licciardello, Colombo, Use of N-acetylcysteine in the management of coronary artery diseases, Cardiologia
Mccarty, Dinicolantonio, Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including in uenza and coronavirus, Prog Cardiovasc Dis, doi:10.1016/j.pcad.2020.02.007
Poppe, Wittig, Jurida, The NF-κB-dependent and -independent transcriptome and chromatin landscapes of human coronavirus 229E-infected cells, PLoS Pathog, doi:10.1371/journal.ppat.1006286
Rumack, Bateman, Acetaminophen and acetylcysteine dose and duration: past, present and future [published correction appears, Clin Toxicol
Schulte-Schrepping, Reusch, Paclik, Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment, Cell, doi:10.1016/j.cell.2020.08.001
Shi, Puyo, N-Acetylcysteine to Combat COVID-19: An Evidence Review, Ther Clin Risk Manag, doi:10.2147/TCRM.S273700
Stegelmeier, Van Vloten, Mould, Myeloid Cells during Viral Infections and In ammation, Viruses, doi:10.3390/v11020168
Sun, Zhang, Li, Xu, A systematic review of chest imaging ndings in COVID-19, Quant Imaging Med Surg, doi:10.21037/qims-20-564
Suter, Domenighetti, Schaller, Laverrière, Ritz et al., N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study, Chest, doi:10.1378/chest.105.1.190
Taher, Lashgari, Sedighi, Rahimi-Bashar, Poorolajal et al., A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome, Pharmacol Rep, doi:10.1007/s43440-021-00296-2
Wu, Tackle the free radicals damage in COVID-19, Nitric Oxide, doi:10.1016/j.niox.2020.06.002
Šalamon, Kramar, Marolt, Poljšak, Milisav, Medical and Dietary Uses of N-Acetylcysteine, Antioxidants, doi:10.3390/antiox8050111
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop